Skip to content

Study suggests immune systems of untreated HIV-infected individuals may deteriorate faster than previously thought

Ten steps to reducing loss to follow up

Earlier treatment could be cost-effective for South Africa

Abacavir as potent as tenofovir for patients starting HIV treatment with a high viral load

Nevirapine matches atazanavir/ritonavir in 48-week study

Genotypic tests matches tropism test in predicting who benefits from CCR5 inhibitors

Aciclovir reduces disease progression and death in people with HIV by nearly 20 per cent

Delays in starting treatment common in ART programmes

`Test and treat` unlikely to halt Washington epidemic